- 1
Campbell E J, Campbell M A, Boukedes S S. et al .
Quantum proteolysis by neutrophils: implications for
pulmonary emphysema in alpha 1-antitrypsin deficiency.
J Clin Invest.
1999;
104
337-344
- 2
Fairbanks K D, Tavill A S.
Liver disease in alpha 1-antitrypsin deficiency: a
review.
Am J Gastroenterol.
2008;
103
2136-2141
- 3
Stoller J K, Aboussouan L S.
Alpha1-antitrypsin deficiency.
Lancet.
2005;
365
2225-2236
- 4
Mahadeva R, Lomas D A.
Genetics and respiratory disease. 2. Alpha 1-antitrypsin
deficiency, cirrhosis and emphysema.
Thorax.
1998;
53
501-505
- 5
Lomas D A, Parfrey H.
Alpha1-antitrypsin deficiency. 4: Molecular
pathophysiology.
Thorax.
2004;
59
529-535
- 6
Crystal R G.
Alpha 1-antitrypsin deficiency, emphysema, and liver disease.
Genetic basis and strategies for therapy.
J Clin Invest.
1990;
85
1343-1352
- 7
American Thoracic Society/European Respiratory Society
Statement .
Standards for the Diagnosis and Management of Individuals
with Alpha-1 Antitrypsin Deficiency.
Am J Respir Crit Care Med.
2003;
168
818-900
- 8
DeMeo D L, Silverman E K.
Alpha1-antitrypsin deficiency. 2: genetic aspects of
alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema
risk.
Thorax.
2004;
59
259-264
- 9
Mahadeva R, Atkinson C, Li Z. et al .
Polymers of Z alpha1-antitrypsin co-localize with neutrophils
in emphysematous alveoli and are chemotactic in vivo.
Am J Pathol.
2005;
166
377-386
- 10
Blanco I, de Serres F J, Fernandez-Bustillo E. et al .
Estimated numbers and prevalence of PI*S and PI*Z
alleles of alpha1-antitrypsin deficiency in European countries.
ERJ.
2006;
27
77-84
- 11
Stockley R A, Luisetti M, Miravitlles M. et al .
Ongoing research in Europe: Alpha One International Registry
(AIR) objectives and development.
ERJ.
2007;
29
582-586
- 12
McElvaney N G, Stoller J K, Buist A S. et al .
Baseline characteristics of enrollees in the National Heart,
Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha
1-Antitrypsin Deficiency Registry Study Group.
Chest.
1997;
111
394-403
- 13
Bals R, Koczulla R, Kotke V. et al .
Identification of individuals with alpha-1-antitrypsin
deficiency by a targeted screening program.
Respir Med.
2007;
101
1217-1218
- 14
Campos M A, Wanner A, Zhang G, Sandhaus R A.
Trends in the diagnosis of symptomatic patients with
alpha1-antitrypsin deficiency between 1968 and 2003.
Chest.
2005;
128
1179-1186
- 15
Sveger T.
Liver disease in alpha1-antitrypsin deficiency detected by
screening of 200 000 infants.
N Engl J Med.
1976;
294
1316-1321
- 16
Piitulainen E, Sveger T.
Effect of environmental and clinical factors on lung function
and respiratory symptoms in adolescents with alpha1-antitrypsin
deficiency.
Acta Paediatr.
1998;
87(11)
1120-1124
- 17
Bernspang E, Sveger T, Piitulainen E.
Respiratory symptoms and lung function in 30-year-old
individuals with alpha-1-antitrypsin deficiency.
Respir Med.
2007;
101
1971-1976
- 18
Anonymous .
Alpha 1-antitrypsin deficiency: memorandum from a WHO
meeting.
Bull World Health Organ.
1997;
75
397-415
- 19
Vogelmeier C, Buhl R, Criée C P. et al .
Leitlinie der Deutschen Atemwegsliga und der Deutschen
Gesellschaft für Pneumologie und Beatmungsmedizin zur Diagnostik und
Therapie von Patienten mit chronisch obstruktiver Bronchitis und
Lungenemphysemen (COPD).
Pneumologie.
2007;
61
e1-e440
- 20
Andreas S, Batra A, Behr J. et al .
Tabakentwöhnung bei COPD. S3 Leitlinie herausgegeben von
der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin.
Pneumologie.
2008;
62
255-272
- 21
Magnussen H, Goeckenjan G, Kohler D. et al .
Leitlinien zur Langzeit-Sauerstofftherapie.
Pneumologie.
2001;
55
454-464
- 22
Tutic M, Bloch K E, Lardinois D. et al .
Long-term results after lung volume reduction surgery in
patients with alpha1-antitrypsin deficiency.
J Thorac Cardiovasc Surg.
2004;
128
408-413
- 23
Sandhaus R A.
alpha1-Antitrypsin deficiency. 6: new and emerging treatments
for alpha1-antitrypsin deficiency.
Thorax.
2004;
59
904-909
- 24
Wencker M, Banik N, Buhl R. et al .
Long-term treatment of alpha1-antitrypsin deficiency-related
pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche
Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study
group.
Eur Respir J.
1998;
11
428-433
- 25
Alpha-1-Antitrypsin Deficiency Registry Study
Group .
Survival and FEV1 decline in individuals with severe
deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry
Study Group.
Am J Respir Crit Care Med.
1998;
158
49-59
- 26
Wencker M, Fuhrmann B, Banik N. et al .
Longitudinal follow-up of patients with alpha(1)-protease
inhibitor deficiency before and during therapy with IV alpha(1)-protease
inhibitor.
Chest.
2001;
119
737-744
- 27
Seersholm N, Wencker M, Banik N. et al .
Does alpha1-antitrypsin augmentation therapy slow the annual
decline in FEV1 in patients with severe hereditary alpha1-antitrypsin
deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von
Lungenerkrankungen (WATL) alpha1-AT study group.
Eur Respir J.
1997;
10
2260-2263
- 28
Dirksen A, Dijkman J H, Madsen F. et al .
A randomized clinical trial of alpha(1)-antitrypsin
augmentation therapy.
Am J Respir Crit Care Med.
1999;
160
1468-1472
- 29
Dirksen A, Piitulainen E, Parr D G. et al .
Exploring the role of CT densitometry: a randomised study of
augmentation therapy in alpha-1 antitrypsin deficiency.
Eur Respir J.
2009;
Feb. 5 [Epub]
- 30
Koczulla R, Bittkowski N, Andress J. et al .
Das Deutsche Register für Personen mit
Alpha-1-Antitrypsin-Mangel – eine Ressource für die
Versorgungsforschung.
Pneumologie.
2008;
62
655-658
Prof. Dr. Dr. R. Bals
Klinik für Innere Medizin mit Schwerpunkt
Pneumologie
Universitätsklinikum Gießen und Marburg
– Standort Marburg
Baldingerstraße 1
35043 Marburg
Email: bals@staff.uni-marburg.de
